Author:
Imaizumi Yoichi,Okada Yohei,Akamatsu Wado,Koike Masato,Kuzumaki Naoko,Hayakawa Hideki,Nihira Tomoko,Kobayashi Tetsuro,Ohyama Manabu,Sato Shigeto,Takanashi Masashi,Funayama Manabu,Hirayama Akiyoshi,Soga Tomoyoshi,Hishiki Takako,Suematsu Makoto,Yagi Takuya,Ito Daisuke,Kosakai Arifumi,Hayashi Kozo,Shouji Masanobu,Nakanishi Atsushi,Suzuki Norihiro,Mizuno Yoshikuni,Mizushima Noboru,Amagai Masayuki,Uchiyama Yasuo,Mochizuki Hideki,Hattori Nobutaka,Okano Hideyuki
Abstract
Abstract
Background
Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the pathophysiology of human PARK2.
Results
Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an accumulation of α-synuclein, α-synuclein accumulation was observed in the postmortem brain of one of the donor patients. This accumulation was also seen in the iPSC-derived neurons in the same patient.
Conclusions
Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology. These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug screening and potential modified therapies for PD.
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Molecular Biology
Cited by
322 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献